Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xenon in Aneurysmal Subarachnoid Hemorrhage
2022-500596-32-00Phase 2Authorised
- Sponsor
- Turku University Hospital
- Start
- Jun 2022
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of xenon in subarachnoid hemorrhage (SAH) (2 arms), sponsored by Turku University Hospital. Primary endpoint: Global fractional anisotropy of white matter (DTI) on first MRI. Planned start Jun 2022; status: authorised.
02
Drugs
xenon
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on 2022-500596-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500596-32-00.